Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies

Overview of attention for article published in Investigational New Drugs, March 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (73rd percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

policy: 2 policy sources
twitter: 2 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 83 Dimensions

Readers on

mendeley: 99 Mendeley

Summary Policy documents X Facebook Dimensions citations

So far, Altmetric has seen 1 public wall post.

Biblioteca Digital de l'Hospital Universitari Vall d'Hebron. ICS, 13 Mar 2018

Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy…